Travere Therapeutics : Corporate Overview – April 2022

Travere Therapeutics Corporate Overview

April 2022

Forward-Looking Statements

This presentation contains forward-looking statements, including statements about our prospects, products, growth projections, competitive position, potential regulatory filings and agency actions, and the anticipated development, timing, data readouts and therapeutic scope of programs in our clinical pipeline. These forward-looking statements may be accompanied by such words as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "target," "will" and other words and terms of similar meaning. You should not place undue reliance on these statements.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including the safety and efficacy of our product candidates, product competition, market acceptance, the occurrence of adverse safety events with our products or product candidates, clinical trials risk, adverse market and economic conditions, regulatory uncertainty, our dependence on collaborations and other third parties over which we may not always have full control, failure to comply with government regulation, our ability to protect our intellectual property rights, and have sufficient rights to market our products and services together with the cost of doing so, problems with our manufacturing processes and our reliance on third parties, the potential impact of the ongoing COVID-19 pandemic, our ability to attract and retain qualified personnel, our level of indebtedness, environmental risks, change of control provisions in our collaborations and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the SEC.

These statements are based on our current beliefs and expectations and speak only as of the date of this presentation. We do not undertake any obligation to publicly update any forward-looking statements.

2

We are in rare for life.

At Travere Therapeutics, we are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent - that is why our global team works with the rare disease community to identify, develop and deliver life-changing

therapies.

Key Strengths of Travere Therapeutics

4

Financial Snapshot

GAAP Reported Financials	FY2021	FY2020	FY2019	FY2018
Net Product Sales	$210.8mm	$198.3mm	$175.3mm	$164.2mm
Operating Expenses	$389.3mm	$374.5mm	$312.7mm	$244.3mm
Operating Income / (Loss)	($161.8mm)	($176.2mm)	($137.4mm)	($80.0mm)
Net Income / (Loss)	($180.1mm)	($169.4mm)	($146.4mm)	($102.7mm)
Cash, Cash Equivalents and Marketable Debt Securities	$552.9mm	$361.6mm	$398.5mm	$471.5mm

• • Shares outstanding as of December 31, 2021: basic ~62mm, diluted ~73mm

• • Convertible notes: $69 million due 2025, $316 million due March 2029

5